| Chemical Properties | Back Directory | [density ]
1.46±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (88.49 mM; Need ultrasonic) | [form ]
Solid | [pka]
11.82±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
RORγt Inverse agonist 6 (compound 43) is a RORγt inverse agonist for the study of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo[1]. | [Biological Activity]
RORγt Inverse agonist 6 (compound 43) is a RORγt inverse agonist for the study of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo[1].
RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in a mouse pharmacodynamics model[1].RORγt Inverse agonist 6 (compound 43) exhibits improved drug exposure (mouse AUC: 1289 ng?h/mL at 1 mg/kg, po)[1].RORγt Inverse agonist 6 (compound 43, 30 mg/kg, po, b.i.d) inhibits the expression level of IL-17A by 59% compared to the vehicle after the oral administration at the tested dose[1]. | [in vivo]
RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in a mouse pharmacodynamics model[1].
RORγt Inverse agonist 6 (compound 43) exhibits improved drug exposure (mouse AUC: 1289 ng?h/mL at 1 mg/kg, po)[1].
RORγt Inverse agonist 6 (compound 43, 30 mg/kg, po, b.i.d) inhibits the expression level of IL-17A by 59% compared to the vehicle after the oral administration at the tested dose[1]. | Animal Model: | Mice[1]. | | Dosage: | 30 mg/kg. | | Administration: | Orally twice: at 30 min before and 8 h after IL-23 administration. | | Result: | Inhibited the expression level of IL-17A by 59% compared to the vehicle after the oral administration at the tested dose.
|
| [storage]
Store at -20°C | [References]
[1]. Sato A, et al. Design and Synthesis of Conformationally Constrained RORγt Inverse Agonists. ChemMedChem. 2019 Oct 28. |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|